Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/jmv.26286 http://scihub22266oqcxt.onion/10.1002/jmv.26286 32644224!7361589!32644224     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32644224&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Med+Virol 2021 ; 93 (2): 755-759 Nephropedia Template TP {{tp|p=32644224|t=2021. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection |pdf=|usr=}}{{32644224}} gab.com Text Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection JO: J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32644224 #FOAvip Hydroxychloroquine sulfate (HCQ) is being scrutinized for repositioning in the treatment and prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This antimalarial drug is also chronically used to treat patients with autoimmune diseases. By analyzing the Portuguese anonymized data on private and public based medical prescriptions we have identified all cases chronically receiving HCQ for the management of diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases. Additionally, we have detected all laboratory confirmed cases of SARS-CoV-2 infection and all laboratory confirmed negative cases in the Portuguese population (mandatorily registered in a centrally managed database). Cross linking the two sets of data has allowed us to compare the proportion of HCQ chronic treatment (at least 2 grams per month) in laboratory confirmed cases of SARS-CoV-2 infection with laboratory confirmed negative cases. Out of 26 815 SARS-CoV-2 positive patients, 77 (0.29%) were chronically treated with HCQ, while 1215 (0.36%) out of 333 489 negative patients were receiving it chronically (P = .04). After adjustment for age, sex, and chronic treatment with corticosteroids and/or immunosuppressants, the odds ratio of SARS-CoV-2 infection for chronic treatment with HCQ has been 0.51 (0.37-0.70). Our data suggest that chronic treatment with HCQ confer protection against SARS-CoV-2 infection. Twit Text FOAVip Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection ????J Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32644224 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32644224 #FOAvip English Wikipedia <ref>{{Cite pmid|32644224}}</ref> Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection #MMPMID32644224 Ferreira A; Oliveira-E-Silva A; Bettencourt P J Med Virol 2021[Feb]; 93 (2): 755-759 PMID32644224show ga Hydroxychloroquine sulfate (HCQ) is being scrutinized for repositioning in the treatment and prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This antimalarial drug is also chronically used to treat patients with autoimmune diseases. By analyzing the Portuguese anonymized data on private and public based medical prescriptions we have identified all cases chronically receiving HCQ for the management of diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases. Additionally, we have detected all laboratory confirmed cases of SARS-CoV-2 infection and all laboratory confirmed negative cases in the Portuguese population (mandatorily registered in a centrally managed database). Cross linking the two sets of data has allowed us to compare the proportion of HCQ chronic treatment (at least 2 grams per month) in laboratory confirmed cases of SARS-CoV-2 infection with laboratory confirmed negative cases. Out of 26 815 SARS-CoV-2 positive patients, 77 (0.29%) were chronically treated with HCQ, while 1215 (0.36%) out of 333 489 negative patients were receiving it chronically (P = .04). After adjustment for age, sex, and chronic treatment with corticosteroids and/or immunosuppressants, the odds ratio of SARS-CoV-2 infection for chronic treatment with HCQ has been 0.51 (0.37-0.70). Our data suggest that chronic treatment with HCQ confer protection against SARS-CoV-2 infection. |*Pre-Exposure Prophylaxis[MESH] |Adult[MESH] |Aged[MESH] |Antimalarials/therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Arthritis, Rheumatoid/*drug therapy/immunology/pathology[MESH] |COVID-19/immunology/*prevention & control/virology[MESH] |Drug Administration Schedule[MESH] |Drug Repositioning[MESH] |Female[MESH] |Humans[MESH] |Hydroxychloroquine/*therapeutic use[MESH] |Lupus Erythematosus, Systemic/*drug therapy/immunology/pathology[MESH] |Male[MESH] |Middle Aged[MESH] |Odds Ratio[MESH] |Portugal[MESH] |Registries[MESH] |Retrospective Studies[MESH]Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection (epmc).pdf DeepDyve Pubget Overpricing